AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience

Official Title

Brief Summary

The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19

Detailed Description

An observational case series of patients with solid organ transplants who have been admitted
with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression
management balancing the treatment of sepsis and avoiding allograft rejection.

Status

Unknown status

Conditions

Solid Organ Transplant Rejection

COVID-19

Eligibility Criteria

Inclusion Criteria:

- Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed
diagnosis of COVID-19

Exclusion Criteria:

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Contacts

Alana Burns
415.287.2420
aburns@caredx.com

NCT Number

NCT04341103

MeSH Terms

COVID-19

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA